Biomarker profiling, as a rapid screening approach for detection of hormone abuse, requires well selected candidate biomarkers and a thorough in vivo biomarker evaluation as previously done for detection of growth hormone doping in athletes. The bovine equivalent of growth hormone, called recombinant bovine somatotropin (rbST) is (il)legally administered to enhance milk production in dairy cows. In this study, first a generic sample pre-treatment and 4-plex flow cytometric immunoassay (FCIA) were developed for simultaneous measurement of four candidate biomarkers selected from literature: insulin-like growth factor 1 (IGF-1), its binding protein 2 (IGFBP2), osteocalcin and endogenously produced antibodies against rbST. Next, bovine serum samples from two extensive controlled rbST animal treatment studies were used for in vivo validation and biomarker evaluation. Finally, advanced statistic tools were tested for the assessment of biomarker combination quality aiming to correctly identify rbST-treated animals. The statistical prediction tool k-nearest neighbours using a combination of the biomarkers osteocalcin and endogenously produced antibodies against rbST proved to be very reliable and correctly predicted 95% of the treated samples starting from the second rbST injection until the end of the treatment period and even thereafter. With the same biomarker combination, only 12% of untreated animals appeared false-positive. This reliability meets the requirements of Commission Decision 2002/657/EC for screening methods in veterinary control. From the results of this multidisciplinary study, it is concluded that the osteocalcin – anti-rbST-antibodies combination represent fit-for-purpose biomarkers for screening of rbST abuse in dairy cattle and can be reliably measured in both the developed 4-plex FCIA as well as in a cost-effective 2-plex microsphere-based binding assay. This screening method can be incorporated in routine veterinary monitoring programmes: in the European Union for detection of rbST abuse and in the control of rbST-free dairy farms in the United States of America and other countries.
References
[1]
Teale P, Barton C, Driver PM, Kay RG (2009) Biomarkers: unrealized potential in sports doping analysis. Bioanalysis 1: 1103–1118.
[2]
Cacciatore G, Eisenberg SW, Situ C, Mooney MH, Delahaut P, et al. (2009) Effect of growth-promoting 17[beta]-estradiol, 19-nortestosterone and dexamethasone on circulating levels of nine potential biomarker candidates in veal calves. Anal Chim Acta 637: 351–359.
[3]
Draisci R, Montesissa C, Santamaria B, D'Ambrosio C, Ferretti G, et al. (2007) Integrated analytical approach in veal calves administered the anabolic androgenic steroids boldenone and boldione: urine and plasma kinetic profile and changes in plasma protein expression. Proteomics 7: 3184–3193.
[4]
Smits NGE, Bremer MGEG, Ludwig SKJ, Nielen MWF (2012) Development of a flow cytometric immunoassay for recombinant bovine somatotropin-induced antibodies in serum of dairy cows. Drug Test Analysis 4: 362–367.
[5]
Chung L, Baxter RC (2009) Detection of growth hormone responsive proteins using SELDI–TOF mass spectrometry. Growth Horm IGF Res 19: 383–387.
[6]
Chung L, Clifford D, Buckley M, Baxter RC (2006) Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab 91: 671–677.
[7]
Ding J, List EO, Okada S, Kopchick JJ (2009) Perspective: Proteomic approach to detect biomarkers of human growth hormone. Growth Horm IGF Res 19: 399–407.
[8]
Ding J, Okada S, J？rgensen JOL, Kopchick JJ (2011) Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. Proteomics 11: 3565–3571.
[9]
Boateng J, Kay R, Lancashire L, Brown P, Velloso C, et al. (2009) A proteomic approach combining MS and bioinformatic analysis for the detection and identification of biomarkers of administration of exogenous human growth hormone in humans. Proteom Clin Appl 3: 912–922.
[10]
Mooney MH, Situ C, Cacciatore G, Hutchinson T, Elliott C, et al. (2008) Plasma biomarker profiling in the detection of growth promoter use in calves. Biomarkers 13: 246–256.
[11]
Powrie JK, Bassett EE, Rosen T, J？rgensen JO, Napoli R, et al. (2007) Detection of growth hormone abuse in sport. Growth Horm IGF Res 17: 220–226.
[12]
Kniess A, Ziegler E, Kratzsch J, Thieme D, Müller R (2003) Potential parameters for the detection of hGH doping. Anal Bioanal Chem 376: 696–700.
[13]
Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosen T, et al. (2000) Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: A double blind, placebo-controlled study. J Clin Endocrinol Metab 85: 1505–1512.
[14]
Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, et al. (2000) The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. J Clin Endocr Metab 85: 4193–4200.
[15]
Erotokritou-Mulligan I, Eryl Bassett E, Cowan DA, Bartlett C, Milward P, et al. (2010) The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Clin Endocrinol 72: 520–526.
[16]
Healy M-L, Dall R, Gibney J, Bassett E, Ehrnborg C, et al. (2005) Toward the development of a test for growth hormone (GH) abuse: A study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J Clin Endocr Metab 90: 641–649.
[17]
Sartorio A, Jubeau M, Agosti F, Marazzi N, Rigamonti A, et al. (2006) A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes. J Endocrinol Invest 29: 237–243.
[18]
Wallace JD, Cuneo RC, Lundberg PA, Rosen T, Jorgensen JOL, et al. (2000) Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 85: 124–133.
[19]
Castigliego L, Grifoni G, Rosati R, Iannone G, Armani A, et al. (2009) On the alterations in serum concentration of somatotropin and insuline-like growth factor 1 in lactating cows after the treatment with a little studied recombinant bovine somatotropin. Res Vet Sci 87: 29–35.
[20]
Zhao X, McBride BW, Trouten-Radford LM, Golfman L, Burton JH (1994) Somatotropin and insulin-like growth factor-I concentrations in plasma and milk after daily or sustained-release exogenous somatotropin administrations. Domest Anim Endocrin 11: 209–216.
[21]
Food and Drug Administration (1993) Animal Drugs, Feeds, and Related Products; Sterile Sometribove Zinc Suspension. 58 Federal Register 59946.
[22]
European Union (1999) Council Decision 1999/879/EC of 17 December 1999 concerning the placing on the market and administration of bovine somatotrophin (BST) and repealing Decision 90/218/EEC. Off J Eur Commun L 331: 71–72.
[23]
European Union (2002) Commission Decision 2002/657/EC of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Off J Eur Commun L 221: 8–36.
[24]
Castigliego L, Iannone G, Grifoni G, Rosati R, Gianfaldoni D, et al. (2007) Natural and recombinant bovine somatotropin: immunodetection with a sandwich ELISA. J Dairy Res 74: 79–85.
[25]
Lucy MC, Byatt JC, Curran TL, Curran DF, Collier RJ (1994) Placental lactogen and somatotropin: hormone binding to the corpus luteum and effects on the growth and functions of the ovary in heifers. Biol Reprod 50: 1136–1144.
[26]
Le Breton MH, Rochereau-Roulet S, Chereau S, Pinel G, Delatour T, et al. (2010) Identification of cows treated with recombinant bovine somatotropin. J Agr Food Chem 58: 729–733.
[27]
Le Breton MH, Rochereau-Roulet S, Pinel G, Cesbron N, Le Bizec B (2009) Elimination kinetic of recombinant somatotropin in bovine. Anal Chim Acta 637: 121–127.
[28]
Bremer MGEG, Smits NGE, Haasnoot W, Nielen MWF (2010) Multiplex ready flow cytometric immunoassay for total insulin like growth factor 1 in serum of cattle. Analyst 135: 1147–1152.
[29]
Ludwig SKJ, Smits NGE, Bremer MGEG, Nielen MWF (2012) Monitoring milk for antibodies against recombinant bovine somatotropin using a microsphere immunoassay-based biomarker approach. Food Control 26: 68–72.
[30]
Rochereau-Roulet S, Gaudin I, Chéreau S, Prévost S, André-Fontaine G, et al. (2011) Development and validation of an enzyme-linked immunosorbent assay for the detection of circulating antibodies raised against growth hormone as a consequence of rbST treatment in cows. Anal Chim Acta 700: 189–193.
[31]
Smits NGE, Ludwig SKJ, Van der Veer G, Bremer MGEG, Nielen MWF (2012) Serum biomarker profiling for detection of recombinant bovine somatotropin abuse using a multiplex flow cytometric immunoassay. Analyst doi: 10.1039/c1032an35226e.
[32]
Kicman AT, Miell JP, Teale JD, Powrie J, Wood PJ, et al. (1997) Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin Endocrinol 47: 43–50.
[33]
Eppard PJ, Rogan GJ, Boysen BG, Miller MA, Hintz RL, et al. (1992) Effect of high doses of a sustained-release bovine somatotropin on antibody formation in dairy cows. J Dairy Sci 75: 2959–2967.
[34]
Zwickl CM, Smith HW, Tamura RN, Bick PH (1990) Somatotropin antibody formation in cows treated with a recombinant bovine somatotropin over two lactations. J Dairy Sci 73: 2888–2895.
[35]
Lee AJ, Hodges S, Eastell R (2000) Measurement of osteocalcin. Ann Clin Biochem 37: 432–446.
[36]
Armstrong JD, Cohick WS, Harvey RW, Heimer EP, Campbell RM (1993) Effect of feed restriction on serum somatotropin, insulin-like growth factor-I-(IGF-I) and IGF binding proteins in cyclic heifers actively immunized against growth hormone releasing factor. Domest Anim Endocrin 10: 315–324.
[37]
Blum WF, Horn N, Kratzsch J, J？rgensen JO, Juul A, et al. (1993) Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regulat 3: 100–104.
[38]
Friedrich N, Alte D, V？lzke H, Spilcke-Liss E, Lüdemann J, et al. (2008) Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: Results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res 18: 228–237.
[39]
Sato R, Onda K, Ochiai H, Iriki T, Yamazaki Y, et al. (2011) Serum osteocalcin in dairy cows: Age-related changes and periparturient variation. Res Vet Sci 91: 196–198.
[40]
Kerr DE, Laarveld B, Fehr MI, Manns JG (1991) Profiles of serum IGF-I concentrations in calves from birth to eighteen months of age and in cows throughout the lactation cycle. Can J Anim Sci 71: 695–705.
[41]
Sharma BK, Vandehaar MJ, Ames NK (1994) Expression of insulin-like growth factor-I in cows at different stages of lactation and in late lactation cows treated with somatotropin. J Dairy Sci 77: 2232–2241.
[42]
R Development Core Team (2011) R: A language and environment for statistical computing.
[43]
Dimitriadou E, Hornik K, Leisch F, Meyer D, Weingessel A (2011) Misc functions of the department of statistics (e1071), TU Wien.
[44]
Efron B (1979) Bootstrap methods: Another look at the jackknife. Ann Stat 7: 1–26.
[45]
Nelson AE, Ho KKY, Ghigo E, Lanfranco F, Strasburger CJ (2011) Detection of growth hormone doping in sport using growth hormone-responsive markers. In: Melmed S, editor. Hormone use and abuse by athletes: Springer US. pp. 139–150.
[46]
Di Luigi L, Rigamonti AE, Agosti F, Mencarelli M, Sgrò P, et al. (2009) Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. Eur J Endocrinol 160: 753–758.
[47]
McGuire MA, Vicini JL, Bauman DE, Veenhuizen JJ (1992) Insulin-like growth factors and binding proteins in ruminants and their nutritional regulation. J Anim Sci 70: 2901–2910.
